ICCC

Insider Trades

Name	Value	Action	Price	Current Price
te Boekhorst Paul Francis OlivierDirector, Officer: President And CEO $76k8k shares BuyJun 18, 2026 $9.50 $9.75
Gathagan Bryan K.Director $6.3k1k shares BuyJun 12, 2025 $6.32 --
Tomsche David ScottDirector $7.8k1.6k shares BuyNov 25, 2025 $4.77 --
Tomsche David ScottDirector $7.8k1.6k shares BuyNov 25, 2025 $4.76 --
te Boekhorst Paul Francis OlivierDirector, Officer: President And CEO $18k3.7k shares BuyDec 2, 2025 $4.87 --
te Boekhorst Paul Francis OlivierDirector, Officer: President And CEO $13k2.6k shares BuyDec 3, 2025 $5.00 --

News

zacks.comICCC's Valuation Remains Premium: Is it Worth Overpaying for?zacks.comJun 18

zacks.comImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demandzacks.comMay 25

marketbeat.comImmuCell Q1 Earnings Call Highlightsmarketbeat.comMay 15

seekingalpha.comImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 15

globenewswire.comImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026globenewswire.comMay 14

Trade ICCC

About ImmuCell Corporation

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

CEO: F. Olivier Te Boekhorst
IPO Date: May 5, 1987

Market Data

Open: $9.29
High: $9.58
Low: $9.29
Volume: 34.2K
Avg Volume: 25.8K
52W High: $10.75
52W Low: $4.52

Valuation

Market Cap: $86M
Enterprise Value: $92M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $1.2M
Revenue: $28M
Net Income: $-1.0M
Cash: $3.8M
Debt: $13M

Events

EarningsAug 13

EPS est. 0.05